Chemotherapy and Rituximab With or Without Total-Body Irradiation and Peripheral Stem Cell Transplant in Treating Patients With Lymphoma
Lymphoma

About this trial
This is an interventional treatment trial for Lymphoma focused on measuring stage I adult diffuse large cell lymphoma, stage III adult diffuse large cell lymphoma, stage IV adult diffuse large cell lymphoma, contiguous stage II adult diffuse large cell lymphoma, noncontiguous stage II adult diffuse large cell lymphoma
Eligibility Criteria
DISEASE CHARACTERISTICS: Histologically confirmed aggressive diffuse large B-cell lymphoma CD20-positive disease Age-adjusted International Prognostic Index II or III defined by the presence of at least 1 of the following: Karnofsky performance status 10-70% Lactate dehydrogenase greater than 200 U/L Stage III or IV disease Positron emission tomography avid measurable disease No CNS involvement PATIENT CHARACTERISTICS: Age: 18 to 64 Performance status: See Disease Characteristics Life expectancy: Not specified Hematopoietic: Absolute neutrophil count greater than 1,000/mm^3 Platelet count greater than 50,000/mm^3 Hepatic: Bilirubin less than 2.0 mg/dL unless history of Gilbert's disease or pattern consistent with Gilbert's disease Hepatitis B surface antigen and hepatitis C antibody negative No chronic, active, or persistent hepatitis Renal: Creatinine no greater than 1.5 mg/dL OR Creatinine clearance greater than 60 mL/min No chronic renal insufficiency Cardiovascular: Ejection fraction at least 50% by echocardiogram or MUGA scan No myocardial infarction within the past 6 months No unstable angina No cardiac arrhythmias except chronic atrial fibrillation Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use effective barrier contraception HIV negative No other medical illness that would preclude study No uncontrolled infection No other malignancy within the past 5 years except curatively treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix PRIOR CONCURRENT THERAPY: Biologic therapy: No prior biologic therapy for malignancy Chemotherapy: No prior chemotherapy for malignancy Endocrine therapy: Prior steroids allowed if received no more than 1 week of therapy Radiotherapy: No prior radiotherapy for malignancy Surgery: No prior surgery for malignancy Other: No other prior therapy for malignancy
Sites / Locations
- Memorial Sloan-Kettering Cancer Center
Arms of the Study
Arm 1
Experimental
Induction R-CHOPac Therapy for patients with B-Cell Lymphoma
Patients received 4 cycles if accelerated R-CHOP (cyclophosphamide. doxorubicin, vincristine and prednisone + rituximab) followed by 3 cycles ICE (ifosfamide, carboplatin and etoposide) consolidation therapy.